



HHCP-I Cryopreserved Plateable Human Hepatocytes for Induction Cell Specification		
Lot HH180518		Batch Release: Sept 27, 2019
Species: Human	Gender: male Size: 168 cm Non-smoker	Age: 68 years Weight: 82 kg
Serology: HAV, HBV, HCV, HIV 1/2: negative		Diagnosis: CCC (Cholangiocellular Carcinoma)
Medical History: Diabetes, Hypertension Medication: Metropolol, Dekristol, Finasterid, Propiverin, Simvastatin, Metformin, Ramipril, Doxazosin, HCT, Madopar, Travoprost, Metamizol		Therapy: hemihepatektomy right w/o Chemotherapy
Cryopreservation: Date: May 18, 2018 Amount per vial: 10.2 x 10 ⁶ cells		Thawing: n=2 Post-thaw viability: 77.4 ± 1.3 % Post-thaw yield per vial: 4.1 ± 0.6 x 10 ⁶ cells Recovery: 40 %
Phase contrast on day 1 after thawing (24well plate) 		Phase contrast on day 3 after thawing (24well plate) 
Recommended seeding density on collagen-coated plates: 24well plate – 540,000 cells/well Use Corning collagen coated plates. Culture in Human Hepatocyte Maintenance Medium (HHMM).		
CYP P450 activity in culture after thawing: Ethoxyresorufin-O-deethylation: Induction with 50 µM Omeprazole	pmol/(mg × min) 18.0 ± 12.3	x-fold induction 8.1

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: A. Ullrich

Verified by: C. Garve